Grace Guoying Zhou News Today : Breaking News, Live Updates & Top Stories | Vimarsana

/PRNewswire/ On August 1, 2022, U.S. time, ImmVira s brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252 targeting Malignant Glioma has.

United statesImmvira ovGuoying zhouDrug administrationMalignant gliomaOrphan drug designationOrphan drug actGrace guoying zhou